Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 107 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: rhIGF-I/rhIGFBP-3 Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Chemical Peels and Fractional Laser on IGF-1 Levels in Skin

NCT03775031
View directory record Official record
Conditions
Skin Cancer
Interventions
Fractional Laser and Chemical Peel
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 25, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder

NCT01970345
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
IGF-1, Placebo/saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
5 Years to 12 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Women in Steady Exercise Research [Formerly Women, Oxidative Stress, Exercise and Estrogens (WOSEE)]

NCT00393172
View directory record Official record
Conditions
Breast Cancer, Obesity
Interventions
exercise
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Role of Cytokines on Growth Hormone Suppression in Premenopausal Women With Rheumatoid Arthritis and the Effect of Treatment With Etanercept

NCT00034060
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy
Interventions
Etanercept
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Not applicable Interventional

Effect of a High Protein Diet on the 24-hour Profile of Ghrelin, GH (Growth Hormone) and IGF-1 (Insulin-like Growth Factor-1)

NCT00108225
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LoBag Diet - test phase, LoBAG Diet - control phase
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
55 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 30, 2014 · Synced Sep 25, 2026, 5:22 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT06930625
View directory record Official record
Conditions
Acromegaly
Interventions
Debio 4126, Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Not applicable Interventional Results available

Physiologic Growth Hormone Effects in HIV Lipodystrophy

NCT00100698
View directory record Official record
Conditions
AIDS, HIV Infections
Interventions
recombinant human growth hormone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 2Phase 3 Interventional

IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome

NCT00368173
View directory record Official record
Conditions
Growth Hormone Insensitivity Syndrome (GHIS), Laron Syndrome
Interventions
rhIGF-I/rhIGFBP-3
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
2 Years to 18 Years
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Sep 25, 2026, 5:22 AM EDT
Terminated Phase 1 Interventional

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

NCT02538627
View directory record Official record
Conditions
Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
MM-151, MM-121, MM-141, trametinib
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Aurora, Colorado • Sandy Springs, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effect of Protein Supplementation on Bone Health in Healthy Older Men and Women

NCT00421408
View directory record Official record
Conditions
Bone Resorption, Osteoporosis
Interventions
Whey protein supplement, Placebo
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
60 Years to 85 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
2
States / cities
Farmington, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 25, 2026, 5:22 AM EDT
Completed No phase listed Observational

Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant

NCT00510315
View directory record Official record
Conditions
Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
Interventions
Questionnaires, Laboratory tests, Abdominal MRI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2020 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of a Nutraceutical in Raising Circulating Serum Vitamin, Mineral and Amino Acid Levels in Patients.

NCT04054505
View directory record Official record
Conditions
Vitamin Deficiency
Interventions
EZPAK, Placebo
Dietary Supplement
Lead sponsor
Optimal Health Research
Other
Eligibility
26 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Growth Hormone and Bone in Obesity

NCT01724489
View directory record Official record
Conditions
Obesity, Osteopenia
Interventions
Growth hormone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Tau Imaging of Chronic Traumatic Encephalopathy

NCT02191267
View directory record Official record
Conditions
Chronic Traumatic Encephalopathy
Interventions
[F18]-T807, [F18]-Florbetapir, MRI/MRS, Genetic Analysis for Genetic Risk Score for Tau.
Radiation · Device · Genetic
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 69 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Growth Hormone Treatment in Children With Phelan McDermid Syndrome

NCT04003207
View directory record Official record
Conditions
Phelan McDermid Syndrome
Interventions
Recombinant human Growth hormone
Drug
Lead sponsor
Swathi Sethuram
Other
Eligibility
2 Years to 12 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

NCT00785941
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
IMC-A12
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)

NCT00233519
View directory record Official record
Conditions
Myotonic Dystrophy
Interventions
SomatoKine/IPLEX
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2012 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 4 Interventional Results available

Effects of Sandostatin LAR® in Acromegaly

NCT01424241
View directory record Official record
Conditions
Acromegaly
Interventions
Sandostatin LAR
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

NCT06021054
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Veligrotug, Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly

NCT01412424
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide capsules
Drug
Lead sponsor
Chiasma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 25, 2026, 5:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

NCT00490100
View directory record Official record
Conditions
Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID), Growth Hormone Resistence
Interventions
Increlex
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 20 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Sep 25, 2026, 5:22 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Prospective Randomized Double Blinded Controlled Trial of Non-Operative Management of TFCC Injuries

NCT03830775
View directory record Official record
Conditions
Wrist Injuries, PRP
Interventions
Platelet-rich plasma (PRP)
Procedure
Lead sponsor
Edna Rath
Federal
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.

NCT00766038
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Recombinant human Growth Hormone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Bakersfield, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 25, 2026, 5:22 AM EDT
Completed Phase 3 Interventional

A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome

NCT00017927
View directory record Official record
Conditions
McCune Albright Syndrome, Polyostotic Fibrous Dysplasia
Interventions
Pegvisomant
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 25, 2026, 5:22 AM EDT